NSE · ALKEM
Alkem Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹3,071 Cr with net profit ₹762 Cr — a 24.83% net margin, versus 21.37% the period before.
Shareholding
As of 2026-09-30
- Promoter49.7%
- Public17.15%
- FII10.32%
- DII22.82%
62,555 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.23× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #10 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,51,075 Cr | 36.65 | 5.05 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,30,972 Cr | 97.74 | 21.57 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,18,693 Cr | 26.12 | 4.27 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,15,267 Cr | 41.17 | 2.96 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,12,442 Cr | 36.21 | 3.18 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,09,044 Cr | 46.73 | 6.23 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,04,903 Cr | 25.85 | 2.67 | 10.13% | 10.88% |
| Lupin Limited | ₹90,558 Cr | 16.07 | 3.76 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹74,507 Cr | 36.78 | 6.65 | 18.07% | 9.22% |
| Alkem Laboratories Ltd.(this company) | ₹61,146 Cr | 28.2 | 4.11 | 13.91% | 13.23% |
AI analysis
AI-generated · google/gemini-2.5-flashAlkem Laboratories Ltd. has a market capitalization of Rs 66514 Cr and reported revenue of Rs 13458.26 Cr in the last fiscal year. The company's EPS stands at Rs 190.79 with a PE ratio of 25.58. Return on equity (ROE) is 19.9% and return on capital employed (ROCE) is 18.6071%. The debt-to-equity ratio is 0.06.
Positives
- +The company has a low debt-to-equity ratio of 0.06.
- +Return on equity (ROE) is 19.9%, indicating efficient use of shareholders' funds.
- +Return on capital employed (ROCE) stands at 18.6071%, reflecting good operational efficiency.
- +Promoter holding of 49.7009% aligns interests with the company's performance, and no shares are pledged.
Negatives
- −Quarterly net profit declined from Rs 765.06 Cr in Sept 2025 to Rs 236.46 Cr in Mar 2026.
- −EPS decreased from Rs 190.79 for the TTM period to Rs 181.11 for the Mar 2025 fiscal year.
- −No dividend yield information is available for Alkem Laboratories Ltd.
Financial Performance
In the fiscal year ending March 2025, Alkem Laboratories Ltd. reported revenue of Rs 13458.26 Cr and a net profit of Rs 2165.48 Cr. For the quarter ending March 2026, the company recorded revenue of Rs 3603.32 Cr and a net profit of Rs 236.46 Cr. Quarterly net profit has seen fluctuations, declining from Rs 765.06 Cr in Sept 2025 to Rs 236.46 Cr in Mar 2026.
Profitability & Returns
The company's P/E ratio is 25.58, and its earnings per share (EPS) for the last fiscal year was Rs 190.79. Alkem Laboratories Ltd. generated a return on equity (ROE) of 19.9% and a return on capital employed (ROCE) of 18.6071%. The annual net profit for Mar 2025 was Rs 2165.48 Cr.
Balance Sheet
Alkem Laboratories Ltd. maintains a low debt-to-equity ratio of 0.06, indicating a limited reliance on borrowed capital. The book value per share is Rs 1030.68. This suggests a strong equity base relative to its debt obligations.
Ownership & Pledges
As of June 30, 2026, promoters held 49.7009% of the shares, with no shares pledged. Foreign Institutional Investors (FIIs) held 10.4164%, and Domestic Institutional Investors (DIIs) held 22.632%. The public shareholding was 17.2507%, with a total of 62822 shareholders.
Data as of — price: 2026-11-14 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.